Skip to main content

The PIVOT-02 trial

By 16 Dicembre 2019Maggio 12th, 2021No Comments

The importance of microenviroment, the influence of the gut microbiota and nutritions on the immunotherapy responce, and the combinations able to break the resistance to immunocheckpoint inhibitors are some of the current challenges facing the international oncology community, gathered at the 10° Melanoma Bridge meeting. That is the opinion of Igor Puzanov (Director of the Early Phase Clinical Trials and Melanoma Program at Roswell Park Cancer Center, Buffalo, New York), met in Naples during the congress, where he focused on the updated results of PIVOT-02 trial about the combination of NKTR-214 plus nivolumab in previously untreated patients with metastatic stage IV melanoma.